Cystatin C is associated with the metabolic syndrome and other cardiovascular risk factors in a hypertensive population

Journal of the American Society of Hypertension

Volumn 3, Issue 3, 2009, Pages 201-209

  Vigil, Luis ^a   Lopez, Manuel ^a   Condés, Emilia ^a   Varela, Manuel ^a   Lorence, Dulce ^b   Garcia Carretero, Rafael ^a   Ruiz, Julian ^a  

^a Hypertension Unit

^b HOSPITAL DE MÓSTOLES   (Spain)

Author keywords

cardiovascular diseases; inflammatory markers; insulin resistance; Kidney function

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 67349265758     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2009.01.002     Document Type: Article

References (48)

1. Filler G., Bökenkamp A., Hofmann W., Le Bricon T., Martinez-Brú C., and Grubb A. Cystatin C as a marker of GFR-history, indications and future research. Clin Biochem 38 (2005) 1-8
2. Dharnidharka V.R., Kwon C., and Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40 (2002) 221-226
3. Fliser D., and Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 37 (2001) 79-83
4. Coll E., Botey A., Alvarez L., Poch E., Quintó L., Saurina A., et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 36 (2000) 29-34
5. Mangge H., Liebmann P., Tanil H., Hermann J., Wagner C., Gallistl S., et al. Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis. Clin Chim Acta 300 (2000) 195-202
6. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
7. Shlipak M.G., Wassel Fyr C.L., Chertow G.M., Harris T.B., Kritchevsky S.B., Tylavsky F.A., et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 17 (2006) 254-261
8. Luc G., Bard J.M., Lesueur C., Arveiler D., Evans A., Amouyel P., et al., PRIME Study Group. Plasma cystatin C and development of coronary heart disease: the PRIME Study. Atherosclerosis 185 (2006) 375-380
9. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.O., and Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 110 (2004) 2342-2348
10. Koenig W., Twardella D., Brenner H., and Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51 (2005) 321-327
11. Ix J.H., Shlipak M.G., Chertow G.M., Ali S., Schiller N.B., and Whooley M.A. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail 12 (2006) 601-607
12. Ix J.H., Shlipak M.G., Chertow G.M., and Whooley M.A. Association of Cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115 (2007) 173-179
13. Zethelius B., Berglund L., Sundström J., Ingelsson E., Basu S., Larsson A., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358 (2008) 2107-2116
14. Knight E.L., Verhave J.C., Spiegelman D., Hillege H.L., de Zeeuw D., Curhan G.C., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65 (2004) 1416-1421
15. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
16. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
17. Chen J., Muntner P., Hamm L.L., Jones D.W., Batuman V., Fonseca V., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140 (2004) 167-174
18. Kurella M., Lo J.C., and Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16 (2005) 2134-2140
19. Zhang L., Zuo L., Wang F., Wang M., Wang S., Liu L.S., et al. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc 82 (2007) 822-827
20. Ninomiya T., Kiyohara Y., Kubo M., Yonemoto K., Tanizaki Y., Doi Y., et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 48 (2006) 383-391
21. Tozawa M., Iseki C., Tokashiki K., Chinen S., Kohagura K., Kinjo K., et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res 30 (2007) 937-943
22. Kitiyakara C., Yamwong S., Cheepudomwit S., Domrongkitchaiporn S., Unkurapinun N., Pakpeankitvatana V., et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int 71 (2007) 693-700
23. Lee J.E., Choi S.Y., Huh W., Kim Y.G., Kim D.J., and Oh H.Y. Metabolic syndrome, C-reactive protein, and chronic kidney disease in nondiabetic, nonhypertensive adults. Am J Hypertens 20 (2007) 1189-1194
24. Lucove J., Vupputuri S., Heiss G., North K., and Russell M. Metabolic syndrome and the development of CKD in American Indians: the Strong Heart Study. Am J Kidney Dis 51 (2008) 21-28
25. Rashidi A., Ghanbarian A., and Azizi F. Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol 2 (2007) 976-983
26. Chen J., Gu D., Chen C.S., Wu X., Hamm L.L., Muntner P., et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant 22 (2007) 1100-1106
27. Locatelli F., Pozzoni P., and Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 17 (2006) S81-S85
28. Retnakaran R., Connelly P.W., Harris S.B., Zinman B., and Hanley A.J. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr Nephrol 22 (2007) 1007-1013
29. Demircan N., Gurel A., Armutcu F., Unalacak M., Aktunc E., and Atmaca H. The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome. Med Sci Monit 14 (2008) 97-101
30. Servais A., Giral P., Bernard M., Bruckert E., Deray G., and Isnard Bagnis C. Is serum cystatin C a reliable marker for metabolic syndrome?. Am J Med 121 (2008) 426-432
31. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
32. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
33. Erlandsen E.J., Randers E., and Kristensen J.H. Evaluation of the Dade-Behring N Latex Cystatin C assay on the Dade-Behring Nephelometer II System. Scand J Clin Lab Invest 59 (1999) 1-8
34. Peralta C.A., Whooley M.A., Ix J.H., and Shlipak M.G. Kidney function and systolic blood pressure new insights from cystatin C: data from the Heart and Soul Study. Am J Hypertens 19 (2006) 939-946
35. Haffner S.M. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 19 (2006) S3-S9
36. Isomaa B., Almgren P., Tuomi T., Forsén B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
37. Shlipak M.G., Praught M.L., and Sarnak M.J. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145 (2006) 237-246
38. Herget-Rosenthal S., Trabold S., Pietruck F., Holtmann M., Philipp T., and Kribben A. Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 20 (2000) 97-102
39. Pucci L., Triscornia S., Lucchesi D., Fotino C., Pellegrini G., Pardini E., et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 53 (2007) 480-488
40. Facchini F., Chen Y.D., Hollenbeck C.B., and Reaven G.M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266 (1991) 3008-3011
41. Schück O., Teplan V., Stollova M., and Skibova J. Estimation of glomerular filtration rate in obese patients with chronic renal impairment based on serum cystatin C levels. Clin Nephrol 62 (2004) 92-96
42. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
43. Rodilla E., Costa J.A., Pérez Lahiguera F., González C., Miralles A., and Pascual J.M. Cystatin C and other cardiovascular markers in hypertension. Med Clin (Barc) 130 (2008) 1-5
44. Jotoku M., Okura T., Enomoto D., Irita J., Miyoshi Y., Kurata M., et al. Association between serum cystatin C and inflammatory cytokines in patients with essential hypertension [abstract]. J Hypertens 26 (2008) S4
45. Palaniappan L., Carnethon M., and Fortmann S.P. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 16 (2003) 952-958
46. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
47. Wachtell K., Ibsen H., Olsen M.H., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Ann Intern Med 139 (2003) 901-906
48. Hillege H.L., Fidler V., Diercks G.F., van Gilst W.H., de Zeeuw D., van Veldhuisen D.J., et al. Prevention of Renal, Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and no cardiovascular mortality in general population. Circulation 106 (2002) 1777-1782